Straits Times Index
3,310.07 -3.41 (-0.10%) S&P 500
5,303.27 +6.17 (+0.12%) Dow
40,003.59 +134.19 (+0.34%) Nasdaq
16,685.97 -12.33 (-0.07%) Bitcoin USD
66,933.28 -161.89 (-0.24%) CMC Crypto 200
1,364.87 +10.45 (+0.77%)
Summit Hotel Properties, Inc. (INN)
Pre-market:
| Previous close | 6.07 |
| Open | 6.10 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 1400 |
| Day's range | 5.98 - 6.10 |
| 52-week range | 5.31 - 7.26 |
| Volume | |
| Avg. volume | 711,011 |
| Market cap | 650.234M |
| Beta (5Y monthly) | 1.95 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.32 (5.32%) |
| Ex-dividend date | 16 May 2024 |
| 1y target est | N/A |
- CNW Group
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the successful pre-clinical treatment with a liposomal-CBD injection in a female donkey. Innocan's innovative therapy provided immediate noticeable pain relief and improved mobility.
- PR Newswire
SUMMIT HOTEL PROPERTIES REPORTS FIRST QUARTER 2024 RESULTS
Summit Hotel Properties, Inc. (NYSE: INN) (the "Company"), today announced results for the three months ended March 31, 2024.
- CNW Group
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan's Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.
